Loading
A phase 2 trial of Trastuzumab rezetecan, Retlirafusp alfa, Capecitabine, Adebrelimab and Oxaliplatin in gastric & gastro-oesophageal junction cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer is a phase 2 interventional study registered as NCT05671822 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 258 participants planned, started 2023-03-14 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine, SHR-A1811, SHR-1316, and capecitabine, SHR-A1811, SHR-1316, capecitabine,and oxaliplatin and SHR-A1811, SHR-1316, and 5-FU.
Shares Trastuzumab rezetecan, HER2-positive gastric cancer, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Retlirafusp alfa, Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.